FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma By Ogkologos - August 8, 2025 527 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LINKER-MM1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration MOST POPULAR Hero Nanny Permanently Injured While Saving 2-Year-Old From Speeding Car About... March 5, 2019 World Cancer Research Day: Celebrating Progress in Treating and Caring for... September 13, 2022 Working Mom with Stage II Breast Cancer Receives Custom Wig Made... July 30, 2020 Jiffy Lube Surprises Volunteer Who Drives Cancer Patients To Treatment With... December 11, 2019 Load more HOT NEWS I Received the COVID-19 Vaccine – Now What? Shortening Duration of Adjuvant Treatment from 6 to 3 Months Did... The Benefits of Yoga During Cancer and How to Get Started Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual TNBC Following Neoadjuvant...
